Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis

The association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and atrial fibrillation (AF) recurrence after catheter ablation among patients with diabetes and AF remains unclear. Patients with AF undergoing initial catheter ablation with a history of diabetes from the China AF registry...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2023-12, Vol.12 (24), p.e031269-e031269
Main Authors: Zhao, Zixu, Jiang, Chao, He, Liu, Zheng, Shiyue, Wang, Yufeng, Gao, Mingyang, Lai, Yiwei, Zhang, Jingrui, Li, Mingxiao, Dai, Wenli, Zuo, Song, Guo, Xueyuan, Li, Songnan, Jiang, Chenxi, Liu, Nian, Tang, Ribo, Long, Deyong, Du, Xin, Sang, Caihua, Dong, Jianzeng, Ma, Changsheng
Format: Article
Language:English
Subjects:
atrial fibrillation
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Atrial Fibrillation - surgery
catheter ablation
Catheter Ablation - adverse effects
Catheter Ablation - methods
diabetes
Diabetes Mellitus - etiology
Glucose
Humans
Original Research
Propensity Score
Prospective Studies
Recurrence
Risk Factors
SGLT2 inhibitor
Sodium
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and atrial fibrillation (AF) recurrence after catheter ablation among patients with diabetes and AF remains unclear. Patients with AF undergoing initial catheter ablation with a history of diabetes from the China AF registry were included. Patients using SGLT2i were identified and matched by propensity score with non-SGLT2i patients in a 1:3 ratio. The main outcome was AF recurrence during the 18-month follow-up. A total of 138 patients with diabetes with SGLT2i therapy and 387 without SGLT2i were analyzed. AF recurrence occurred in 37 patients (26.8%) in the SGLT2i group and 152 patients (39.3%) in the non-SGLT2i group during a total of 593.3 person-years follow-up. The SGLT2i group was associated with lower AF recurrence compared with the non-SGLT2i group (hazard ratio, 0.63 [95% CI, 0.44-0.90], =0.007). A total of 4 studies were analyzed in our meta-analysis demonstrating that SGLT2i was associated with lower AF recurrence after catheter ablation (odds ratio, 0.61 [95% CI, 0.54-0.69];
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.123.031269